Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Tag
phase-2
Tetrandrine trial will test prevention of lung injury during esophageal chemoradiotherapy
A randomized phase II trial will test whether intravenous tetrandrine reduces grade 2 or higher lung injury from 25% to 10%.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.